New lipid formulation of amphotericin B: spectral and microscopic analysis
- PMID: 15328049
- DOI: 10.1016/j.bbamem.2004.05.003
New lipid formulation of amphotericin B: spectral and microscopic analysis
Abstract
UV-visible and dichroic spectrum analysis and electron microscopy have been used to characterize a new amphotericin B (AmB) lipid formulation prepared by a solvent displacement process. The composition was dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) in molar ratio DMPC/DMPG/AmB 7:3:5, a similar composition to that of Abelcet. Although the latter has a "ribbon-like" structure, our process gave a thin disc-like structure. Analysis of circular dichroism (CD) and UV-visible spectra of formulations containing different percentages of AmB revealed that a minimum of AmB self-association was observed with 7:3:5 molar ratio. Varying the lipid ratio (DMPC/DMPG) while maintaining the fixed ratio of AmB yielded similar results when DMPC was in excess (DMPC/DMPG from 10:0 to 6:4). However, when the ratio was between 5:5 to 3:7, AmB self-aggregation increased. For compositions rich in DMPG (2:8 and 0:10), inversion of the CD spectrum was observed. The influence of the lipid composition on the morphology of the complex was also evident in electron microscopy. DMPC/DMPG/AmB (10:0:5) gave large unfracturable lamellae. The presence of DMPG shortened the lamellae, which often appeared as disc-like structures. AmB content, the presence of DMPG and the preparation process all contribute to generating these original structures with particular CD spectra.
Similar articles
-
NMR and ESR study of amphotericin B interactions with various binary phosphatidylcholine/phosphatidylglycerol membranes.Int J Pharm. 2017 Apr 15;521(1-2):384-394. doi: 10.1016/j.ijpharm.2017.02.034. Epub 2017 Feb 16. Int J Pharm. 2017. PMID: 28216467
-
Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins.Antimicrob Agents Chemother. 1993 Feb;37(2):246-50. doi: 10.1128/AAC.37.2.246. Antimicrob Agents Chemother. 1993. PMID: 8452354 Free PMC article.
-
Phase behaviour of amphotericin B multilamellar vesicles.Biochim Biophys Acta. 1991 Feb 25;1062(2):220-6. doi: 10.1016/0005-2736(91)90396-p. Biochim Biophys Acta. 1991. PMID: 1848451
-
The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.Oncol Nurs Forum. 1998 Jan-Feb;25(1):35-48. Oncol Nurs Forum. 1998. PMID: 9460772 Review.
-
Disseminated visceral fusariosis treated with amphotericin B-phospholipid complex.Leuk Lymphoma. 1993 Mar;9(4-5):385-92. doi: 10.3109/10428199309148539. Leuk Lymphoma. 1993. PMID: 8348074 Review.
Cited by
-
Immune Implications of Cholesterol-Containing Lipid Nanoparticles.ACS Nano. 2024 Oct 22;18(42):28480-28501. doi: 10.1021/acsnano.4c06369. Epub 2024 Oct 10. ACS Nano. 2024. PMID: 39388645 Review.
-
Assessing the role of membrane lipids in the action of ruthenium(III) anticancer compounds.Front Mol Biosci. 2023 Jan 4;9:1059116. doi: 10.3389/fmolb.2022.1059116. eCollection 2022. Front Mol Biosci. 2023. PMID: 36660430 Free PMC article.
-
Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery.Pulm Pharmacol Ther. 2020 Oct;64:101975. doi: 10.1016/j.pupt.2020.101975. Epub 2020 Oct 31. Pulm Pharmacol Ther. 2020. PMID: 33137515 Free PMC article.
-
Leishmaniasis in humans: drug or vaccine therapy?Drug Des Devel Ther. 2017 Dec 22;12:25-40. doi: 10.2147/DDDT.S146521. eCollection 2018. Drug Des Devel Ther. 2017. PMID: 29317800 Free PMC article. Review.
-
Development of novel docetaxel phospholipid nanoparticles for intravenous administration: quality by design approach.AAPS PharmSciTech. 2015 Aug;16(4):855-64. doi: 10.1208/s12249-014-0274-9. Epub 2015 Jan 13. AAPS PharmSciTech. 2015. PMID: 25583303 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources